Literature DB >> 23322116

Novel therapies for the treatment of advanced prostate cancer.

J M Clarke1, A J Armstrong.   

Abstract

In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23322116      PMCID： PMC3591460          DOI： 10.1007/s11864-012-0222-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  81 in total

1.  Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Authors:  Henk M W Verheul; David Z Qian; Michael A Carducci; Roberto Pili
Journal:  Cancer Chemother Pharmacol       Date:  2007-01-26       Impact factor: 3.333

2.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Authors:  Raymond J Andersen; Nasrin R Mawji; Jun Wang; Gang Wang; Simon Haile; Jae-Kyung Myung; Kate Watt; Teresa Tam; Yu Chi Yang; Carmen A Bañuelos; David E Williams; Iain J McEwan; Yuzhou Wang; Marianne D Sadar
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

3.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

Authors:  Josep Domingo-Domenech; Samuel J Vidal; Veronica Rodriguez-Bravo; Mireia Castillo-Martin; S Aidan Quinn; Ruth Rodriguez-Barrueco; Dennis M Bonal; Elizabeth Charytonowicz; Nataliya Gladoun; Janis de la Iglesia-Vicente; Daniel P Petrylak; Mitchell C Benson; Jose M Silva; Carlos Cordon-Cardo
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

4.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

Review 5.  Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Authors:  Erica L Mayer; Ian E Krop
Journal:  Clin Cancer Res       Date:  2010-07-15       Impact factor: 12.531

6.  SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

Authors:  Oleg Tatarov; Thomas J Mitchell; Morag Seywright; Hing Y Leung; Valerie G Brunton; Joanne Edwards
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

7.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

10.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962
View more
  6 in total

Review 1.  Targeting fibroblast growth factor pathways in prostate cancer.

Authors:  Paul G Corn; Fen Wang; Wallace L McKeehan; Nora Navone
Journal:  Clin Cancer Res       Date:  2013-09-19       Impact factor: 12.531

2.  Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Authors:  A Mavrou; K Brakspear; M Hamdollah-Zadeh; G Damodaran; R Babaei-Jadidi; J Oxley; D A Gillatt; M R Ladomery; S J Harper; D O Bates; S Oltean
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

3.  BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.

Authors:  Ping Zhao; Jacob Hall; Mary Durston; Austin Voydanoff; Elizabeth VanSickle; Shannon Kelly; Abhinav B Nagulapally; Jeffery Bond; Giselle Saulnier Sholler
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

4.  Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.

Authors:  Inna Serganova; Ekaterina Moroz; Ivan Cohen; Maxim Moroz; Mayuresh Mane; Juan Zurita; Larissa Shenker; Vladimir Ponomarev; Ronald Blasberg
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

5.  SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.

Authors:  Athina Mavrou; Sebastian Oltean
Journal:  Pharmacol Res       Date:  2016-03-16       Impact factor: 7.658

Review 6.  Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine.

Authors:  Sudath Hapuarachchige; Dmitri Artemov
Journal:  Front Oncol       Date:  2020-07-22       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.